Real-Time Tissue Oxygenation Status
Client
ViOptix
Practice Areas
Challenge
ViOptix engaged with Triple Ring Technologies in a co-development partnership to design and develop their Intra.Ox non-invasive, quantitative, handheld tissue oxygenation monitor. Design requirements included real-time tissue monitoring inside the surgical theater with high sensitivity and reliability. Technical challenges faced in the Intra.Ox product development program included:
- Design of an easy-to-use multi-wavelength tissue oximeter
- Smart algorithms to automatically compensate for variable tissue morphologies
- Handheld form factor
- Reusable packaging
- Unlimited readings within a surgery case
Outcomes
The ViOptix Intra.Ox technology received FDA clearance after the company and Triple Ring demonstrated its capability to produce accurate, instantaneous estimation of percent saturated oxygen (St02) without the need for capital equipment or dye injection. The Intra.Ox device is now used at various stages of tissue transfer surgery to positively affect clinical and financial outcomes.
Value Propositions
- Deep, relevant clinical and technical domain knowledge
- Concept to clinical validation and FDA 510k clearance in 18 months
- Complex modeling, including Monte Carlo simulations to accelerate design process
- Urgency to drive value and support fundraising
- Capital efficient, variable resource R&D expertise tailored to the needs of a virtual startup
Real-Time Tissue Oxygenation Status
Challenge
ViOptix engaged with Triple Ring Technologies in a co-development partnership to design and develop their Intra.Ox non-invasive, quantitative, handheld tissue oxygenation monitor. Design requirements included real-time tissue monitoring inside the surgical theater with high sensitivity and reliability. Technical challenges faced in the Intra.Ox product development program included:
- Design of an easy-to-use multi-wavelength tissue oximeter
- Smart algorithms to automatically compensate for variable tissue morphologies
- Handheld form factor
- Reusable packaging
- Unlimited readings within a surgery case
Outcomes
The ViOptix Intra.Ox technology received FDA clearance after the company and Triple Ring demonstrated its capability to produce accurate, instantaneous estimation of percent saturated oxygen (St02) without the need for capital equipment or dye injection. The Intra.Ox device is now used at various stages of tissue transfer surgery to positively affect clinical and financial outcomes.
Value Propositions
- Deep, relevant clinical and technical domain knowledge
- Concept to clinical validation and FDA 510k clearance in 18 months
- Complex modeling, including Monte Carlo simulations to accelerate design process
- Urgency to drive value and support fundraising
- Capital efficient, variable resource R&D expertise tailored to the needs of a virtual startup
Client
ViOptix
Practice Areas
Background
Assessing tissue viability during surgery enables early intervention to improve patient outcomes post-surgery. ViOptix came to Triple Ring seeking solutions for capturing oxygen concentration in resected tissue while mitigating artifacts from surrounding tissue components. The teams worked side-by-side to invent novel solutions at the subsystem and system level, creating a product that promotes faster surgical recovery times, benefitting patients and the hospitals that care for them.
A great thing about working at Triple Ring is that we can both see a wide variety of projects and technologies and develop key technologies that go all the way from concept to treating patients.” The relationship works well for the client also. Scott Coleridge, the ViOptix CEO observes, “Triple Ring has served as our development and engineering group since we decided to go virtual. I don’t think we could have found a higher caliber of scientists and engineers under one roof. They are flexible to work with and have grown with our needs. I would highly recommend them.
ViOptix
Scott Coleridge, (CEO) and Mark Lonsinger, (GM) are family now and we treat ViOptix like it’s our own company,” says Kate Bechtel as she describes ViOptix, a Triple Ring client aiming to improve surgical outcomes through the deployment of technology that can easily measure soft-tissue health in the operating room.
Triple Ring
